<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Target to Lead Selection for ADCs and Biologics

Journey through the drug discovery pipeline from target discovery to in vivo pharmacology. Take advantage of the Largest biobank of patient-derived models, Model development capabilities, Cell-based assays for Screening ADCs, and advanced downstream analysis.

Learn More

Immuno-oncology Targets & Combinations

Leverage comprehensive in vitro, in vivo, ex vivo, and in silico platforms, utilizing immunocompetent, humanized, or patient-derived models. With robust biomarker analysis and a focus on checkpoint inhibitors, you can optimize combination strategies.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

How to Develop Predictive Cancer Biomarkers

key steps showing how to develop predictive cancer biomarkersHow to develop predictive cancer biomarkers: Explore the different types and classes of cancer biomarker, and the key steps of predictive cancer biomarker development.

Advances in Oncology Precision Medicine

Advances in technology coupled with an increased interest in individualized therapies have led to the rapid expansion of precision medicine in oncology over the last few years. Precision medicine uses biomarkers to determine an optimal treatment strategy (using a targeted therapy) and assesses treatment efficacy and/or disease progression in patients.

Precision medicine approaches have fueled strategies leading to improvements in drug efficacy and patient safety, while also reducing the attrition rate of anticancer agents. The Personalized Medicine Coalition states that personalized medicines accounted for 42% of all US FDA drug approvals in 2018, and this is expected to increase over time.

Precision approaches are not a new concept - blood typing, for instance, has been used for decades. However, recent years have witnessed transformational advancements in computational power and algorithms, as well as breakthroughs in genomic technologies including next-generation sequencing (NGS) and other “-omic” signatures (e.g. proteomic and metabolomic).

Enabling Precision Medicine by Developing Cancer Biomarkers and Companion Diagnostics

These major advancements are enabling systems biology approaches that are generating novel opportunities in the field of precision medicine. This includes cancer biomarker discovery and validation strategies to identify promising candidate therapies at an early stage. The overall goal is to tailor novel therapeutics for specific patient populations and cancer indications.

Successful precision medicine strategies require two components:

  1. A targeted therapy
  2. A companion diagnostic (CDx) to confirm the presence of relevant biomarkers, such as genetic mutations, proteins, or other signatures.

In addition to predicting treatment response, the clinical benefits of combining these two components extend to diagnosing disease and assessing treatment effectiveness or disease progression.

Creating a biomarker strategy early in drug development offers the best opportunity for selecting optimal targets and models for the preclinical stage. Using those targets can enhance the probability that preclinical biomarkers will translate to the clinic, to improve trial and patient outcomes. An early biomarker strategy also offers ample opportunity to develop a CDx, which will be required for such translation.

While cancer biomarker development presents many challenges, there are key steps that should be taken into account to provide the best opportunity to bridge the chasm between initial biomarker discovery studies and their clinical translation. In this post, we explore the different types and classes of biomarker which can be developed, and the key steps in predictive cancer biomarker development.

Different Types of Cancer Biomarkers

We’ve previously discussed in more detail the three main types of cancer biomarkers, which are based on their application:

  • Diagnostic biomarkers: To detect or confirm the presence of a specific disease or condition.
  • Predictive biomarkers: To guide treatment decisions by indicating the probable effect of a specific therapy on a patient. These biomarkers identify individuals who are more likely to experience a positive or negative effect.
  • Prognostic biomarkers: To inform about the increased or decreased likelihood of clinical outcomes, such as disease recurrence or progression.

Different Classes of Cancer Biomarkers

There are a wide variety of potential biomarkers relevant to cancer drug development. These are often assessed by measuring levels of proteins, peptides, DNA, RNA, or other biomolecules. As discussed in an earlier post, the different types and classes of cancer biomarkers can be broadly classified as follows:

  • Genetic biomarkers are DNA sequences associated with an increased or decreased risk for developing a disease. This class of biomarkers can be used for cancer diagnosis and prognosis and predicting response to treatment.
  • Epigenetic biomarkers are indicative of altered gene functions that do not involve changes in DNA sequences. This class of biomarkers commonly includes changes in the DNA methylation status and chromatin modifications.
  • Transcriptomic biomarkers are derived from the global measurement of mRNA expression (i.e. transcriptomics). This class of biomarkers provides both measurements of single gene activity and a tissue-specific deeper understanding of cancer molecular subtypes.
  • Proteomic biomarkers provide key information about proteins, including functionality, post‐translational modifications, interaction with other biological molecules, and response to environmental factors. Advances in mass spectrometry have enabled proteomic workflows that allow for profiling large datasets with very high precision and resolution.
  • Metabolomic biomarkers are particularly promising because an altered metabolism is considered a hallmark of cancer. This class of biomarkers can delineate the mechanisms of metabolic pathway changes to facilitate earlier cancer detection and also predict drug responsiveness and contribute to novel therapeutic strategies.

Developing Predictive Cancer Biomarkers

Predictive cancer biomarkers are key to accurately stratifying patients who are most likely to benefit from a targeted therapy, from a safety or efficacy perspective. In addition, trials that incorporate a biomarker strategy have shown higher overall success probabilities than trials without biomarkers.

Despite the advancements in technology and value of biomarkers, there are challenges associated with translation to the clinic. Therefore, it’s important to integrate a biomarker strategy early in the drug development process, which should include a robust biomarker development method to increase the chances of success. We’ve summarized a list of the key steps to consider when developing a predictive cancer biomarker.

Biomarker Discovery

This first step entails exploratory studies and/or retrospective analyses to identify potentially useful biomarkers. Biomarker discovery involves the comprehensive molecular characterization of the clinical outcome of interest, as assessed by an established clinical endpoint. In general, for predictive biomarkers, the endpoint of interest is improved overall survival following treatment with the drug.

The discovery of a biomarker with clinical utility is possible during the preclinical stage by using experimental systems, such as:

  • In vitro models using a 2D cellular or 3D patient-derived xenograft organoid (PDXO) screen
    and/or
  • In vivo mouse clinical trial (MCT) patient-derived xenograft (PDX) models in both in vivo and in vitro experimental systems.

In particular, individual PDX(O) models with well-defined genetic profiles can be very informative about a drug’s mechanism of action.

The key factors for success are

  • Commitment to biomarker discovery at an early stage
  • Access to a wide number/range of PDXs, with available molecular characterization and that replicate clinical diversity
  • Appropriate selection of PDX(O) models based on molecular data and/or a biomarker hypothesis generated using in vitro data.

Assay Development and Analytical Validation

The second step is assay development to objectively measure the biomarker. This is followed by analytical validation to assure that the assay meets acceptable standards of performance in sensitivity, selectivity, precision, accuracy, and reproducibility. It is important to note that this validates its technical performance but not its usefulness.

Clinical Validation and Utility

The final step is assessing clinical validity and utility via an analytically validated assay during a clinical trial, with multiple design options depending on the intended use of the test and availability of specimens from previous clinical trials.

Clinical validity relates to the observation that the predictive assay reliably divides the patient population(s) of interest into distinct groups with divergent expected outcomes to a specific treatment. Simply, this means that the biomarker, through its test, should be able to predict or measure the relevant clinical outcome in pretreatment samples from patients treated with a specific therapy. For example, the PD-L1 immunohistochemistry test is an approved companion diagnostic to pembrolizumab for non-small-cell lung carcinoma (NSCLC) and was used to determine clinical trial eligibility.

One of the most common reasons why biomarkers fail clinical validation is bias or systematic error that is unrelated to clinical outcomes and not reproducible. Sources of bias may include:

  1. Differences in relevant demographic characteristics
  2. Differences in pre-analytic variables (e.g. sample handling, storage time)
  3. Divergence from assay protocols.

Clinical utility is a measure of whether clinical use of the test improves patient outcomes for a specific indication (that is, the final test results support specific decisions/actions that lead to an improvement of patient overall survival beyond the current standard of care). For example, two different clinical trials supported PD-L1 immunohistochemistry tests in NSCLC tissue as a companion diagnostic to pembrolizumab and nivolumab.

Likewise, there are challenges associated with clinical utility. Observational data alone is not acceptable for gene variants associated with complex disorders. Rather, determining whether a test has adequate predictive value for clinical use requires controlled comparisons with alternative test options.

Clinical Implications

There are three key issues associated with implementing a biomarker test in the clinic:

  1. Regulatory authorities’ approval
  2. Acceptability to physicians and patients
  3. Impact on the cost-effectiveness of anticancer treatments.

Addressing these issues is essential.

Understanding the regulatory process is important in developing a predictive cancer biomarker. If an assay is developed as an in vitro diagnostic, then the FDA must approve it. For a laboratory-developed test, only analytic validation is needed for commercialization. The FDA established a biomarker qualification program to facilitate the regulatory/industry/academic interface on biomarker development. Additionally, the agency created a regulatory framework that divides biomarkers into exploratory, probable valid, and known valid, each of which can be applied in defined situations during drug development or in the clinic.

There are different tools and analyses that can aid in determining the acceptability to physicians and patients and the impact on the cost-effectiveness of anticancer treatments. The earlier these factors are considered in the drug development program, the more likely they can be optimized so that the potential success of an investigational agent is maximized.

Conclusion

Cancer biomarkers are crucial to discovering and developing novel cancer therapeutics. Devising a biomarker strategy early in the drug development process can help in selecting optimal targets and models for preclinical studies. In turn, this can enhance the probability of success for your preclinical studies while also maximizing the chances for the biomarkers to translate to the clinic. Early biomarker strategies also offer plenty of opportunity to develop a CDx, which will be required for such translation.

Predictive cancer biomarkers are important for making informed risk/benefit assessments that are relevant for individual patients and they can delineate patient populations who would benefit from a targeted therapy or inform dosing or potential safety risks. By linking therapeutics with diagnostics, biomarkers promise to play an important role in advancing personalized medicine.


Related Posts